Video
Dr. Weber discusses cardiovascular safety of vibegron in patients with OAB
Author(s):
“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.
Video Player is loading.
In this video, Michael A. Weber, MD, discusses the takeaways of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.
Related Videos
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Related Content
